Open Access

Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36

  • Authors:
    • Yingying Shen
    • Jing Zhong
    • Jianghua Liu
    • Kehuang Liu
    • Jun Zhao
    • Ting Xu
    • Ting Zeng
    • Zhimei Li
    • Yajun Chen
    • Wenjun Ding
    • Gebo Wen
    • Xuyu Zu
    • Renxian Cao
  • View Affiliations

  • Published online on: April 2, 2018     https://doi.org/10.3892/or.2018.6350
  • Pages: 2604-2612
  • Copyright: © Shen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer is one of the most common malignancies in females, and 17β-estradiol (E2)/estrogen receptor α (ERα) signaling plays an important role in the initiation and progression of breast cancer. The role of the ER-α subtype and its co-regulator in the initiation of breast cancer and the occurrence of tamoxifen resistance remains to be further elucidated. In our previous studies, protein arginine N-methyltransferase 2 (PRMT2), a co-regulator of estrogen receptor-α (ER-α), was confirmed to interact with ER-α66 and has the ability to inhibit cell proliferation in breast cancer cells. In the present study, we found that tamoxifen treatment induced a decrease in PRMT2 and an increase in ER-α36 as well as ER-α36-mediated non-genomic effect in MDA-MB-231 cells, which were relatively resistant to tamoxifen by contrast to MCF-7 cells. Moreover, PRMT2 was able to interact with ER-α36 directly, suppress ER-α36 and downstream PI3K/Akt and MAPK/ERK signaling, reversing the tamoxifen resistance of breast cancer cells. The present study may be meaningful for understanding the role of PRMT2 in breast cancer progression and for developing a new endocrine therapeutic strategy for breast cancer patients with tamoxifen resistance.
View Figures
View References

Related Articles

Journal Cover

June-2018
Volume 39 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shen Y, Zhong J, Liu J, Liu K, Zhao J, Xu T, Zeng T, Li Z, Chen Y, Ding W, Ding W, et al: Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36. Oncol Rep 39: 2604-2612, 2018
APA
Shen, Y., Zhong, J., Liu, J., Liu, K., Zhao, J., Xu, T. ... Cao, R. (2018). Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36. Oncology Reports, 39, 2604-2612. https://doi.org/10.3892/or.2018.6350
MLA
Shen, Y., Zhong, J., Liu, J., Liu, K., Zhao, J., Xu, T., Zeng, T., Li, Z., Chen, Y., Ding, W., Wen, G., Zu, X., Cao, R."Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36". Oncology Reports 39.6 (2018): 2604-2612.
Chicago
Shen, Y., Zhong, J., Liu, J., Liu, K., Zhao, J., Xu, T., Zeng, T., Li, Z., Chen, Y., Ding, W., Wen, G., Zu, X., Cao, R."Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36". Oncology Reports 39, no. 6 (2018): 2604-2612. https://doi.org/10.3892/or.2018.6350